Ocular Therapeutix, Inc (OCUL) — 10-Q Filings
All 10-Q filings from Ocular Therapeutix, Inc. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 5, 2026
-
Ocular Therapeutix Q3 Loss Widens on Soaring R&D Costs
— Nov 4, 2025 Risk: high
Ocular Therapeutix, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $201.285 million, a substantial rise -
Ocular Therapeutix's Net Loss Widens Amid Rising R&D Costs
— Aug 5, 2025 Risk: high
OCULAR THERAPEUTIX, INC reported a net loss of $29.8 million for the three months ended June 30, 2025, a significant increase from the $21.5 million net loss in -
Ocular Therapeutix Q1 2025 10-Q Filed
— May 5, 2025 Risk: medium
Ocular Therapeutix, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported a Derivative Gain/Loss on Derivative and Other Net, with spec -
Ocular Therapeutix Q3 2024: Assets $156.7M, Liabilities $115M
— Nov 14, 2024 Risk: medium
Ocular Therapeutix, Inc. reported its financial results for the quarter ended September 30, 2024. The company's total assets were $156.7 million, and total liab -
Ocular Therapeutix 10-Q: Assets vs. Liabilities
— Aug 7, 2024 Risk: medium
Ocular Therapeutix, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $155,624,363 and total liabilities of $114,963 -
Ocular Therapeutix, Inc. Files 10-Q for Period Ending March 31, 2024
— May 7, 2024 Risk: medium
OCULAR THERAPEUTIX, INC (OCUL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Ocular Therapeutix, Inc. filed a 10-Q report for the quarterly perio
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX